Form D · Biotechnology
ImmunityBio, Inc.
San Diego, CA · CIK 0001326110
Offering snapshot reported Sep 22, 2023 · SEC filing
- Reported sold
- $470M Offering amount: $470M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 11, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 22, 2023 | Initial | $469,986,600 | No comparison | 3 | SEC filing |
| Jul 22, 2022 | Initial | $10,656,035 | No comparison | 6 | SEC filing |
| Aug 5, 2015 | Initial | $17,000,000 | No comparison | 1 | SEC filing |
| Jul 17, 2015 | Amendment | $78,004,041 | $7,000,000vs Jun 24, 2015 | 11 | SEC filing |
| Jun 24, 2015 | Initial | $71,004,041 | No comparison | 9 | SEC filing |
| Jan 5, 2015 | Initial | $47,495,481 | No comparison | 1 | SEC filing |
| Dec 29, 2014 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Apr 17, 2014 | Initial | $6,504,875 | No comparison | 48 | SEC filing |
| Oct 9, 2009 | Initial | $425,700 | No comparison | 14 | SEC filing |
| Apr 29, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1M
- Finders' fees
- $0
- Form D file number
- 021-492829
Exchange of $269,986,600 in convertible notes for common stock; issuance of $200 mil convertible note
Nant Capital, LLC received an origination fee of $1 mil in connection with the issuance of the $200 mil convertible promissory note.
Source: Form D, filed Sep 22, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Adcock | Director, Executive |
| Michael Blaszyk | Director |
| John Brennan | Director |
| Wesley Clark | Director |
| Cheryl Cohen | Director |
| Richard Gomberg | Executive |
| Steve Gorlin | Director |
| Steven Gorlin | Director |
| Ronald Herberman | Director |
| Henry Ji | Director |
| Henry Ji, Ph.D. | Director |
| Hans G. Klingemann | Director |
| Hans Klingemann, M.D., Ph.D. | Director |
| Hans Klingermann | Director |
| Richard Kusserow | Director |
| Linda Maxwell | Director |
| John Potts | Director |
| John T. Potts, Jr., M.D. | Director |
| Robert Rosen | Director |
| David Sachs | Executive |
| Christobel Selecky | Director |
| Barry Simon | Director |
| Barry J. Simon, M.D. | Director, Executive |
| Patrick Soon Shiong | Director, Executive |
| Patrick Soon Shiong, M.D. | Director, Executive |
| John Thomas | Director |
| John C. Thomas, Jr. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3530 John Hopkins Court
San Diego, CA, 92121
San Diego, CA, 92121